Journal article
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies
G Comi, R Alroughani, AL Boster, AD Bass, R Berkovich, Ó Fernández, HJ Kim, V Limmroth, J Lycke, RAL Macdonell, B Sharrack, BA Singer, P Vermersch, H Wiendl, T Ziemssen, A Jacobs, N Daizadeh, CE Rodriguez, A Traboulsee, DP Baker Show all
Multiple Sclerosis Journal | SAGE PUBLICATIONS LTD | Published : 2020
Abstract
Background: Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. Objective: To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis) studies and their extensions. Methods: Subgroups were based on the number of additional alemtuzumab courses received. Exclusion criteria: other disease-modifying therapy (DMT); <12-month follow-up after last alemtuzumab course. Results: In the additional-courses groups, Courses 3 and 4 reduced annualized relapse rate (12 months before: 0.73 and 0.74, respectively; 12 months after: 0.07 and 0.08)...
View full abstractGrants
Awarded by Bayer
Funding Acknowledgements
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Editorial support for the development of this paper was funded by Sanofi. The CARE-MS, CAMMS03409, and TOPAZ studies were funded by Sanofi and Bayer HealthCare Pharmaceuticals.